Will FDA Inspections Ever Be the Same?
FDA's plans to resume inspections of some US regulated facilities this week are not clear on which sites will be visited and what alternative oversight strategies will apply where on-site inspections are difficult.
FDA announced recently that it plans to resume inspections of some U.S. regulated facilities this week, but it’s not clear how it will decide which sites to visit and what alternative oversight strategies will apply where on-site inspections are difficult. Yet, the resurgence in COVID-19 cases in the U.S. looks to limit actual inspections and require FDA to rely more on “virtual” inspections or “paper reviews.” The prospect of further delays in initiating foreign inspections, moreover, raises a host of questions about assuring access to the growing volume of drugs and active ingredients produced overseas and may boost collaboration with foreign inspectorates to vet their local facilities. Overriding all these planning efforts, however, is the expectation that multiple new COVID-19 vaccines and therapeutics will seek regulatory approval in the coming months and will require full FDA vetting of production facilities, operations and records to allay consumer fears about product safety and quality.
Last March 2020, FDA halted most foreign and then domestic field inspections, citing the need to protect staff overseas and the agency’s ability
During this inspection hiatus, FDA has conducted some “mission critical” site visits, but has not provided details as to where such oversight has been warranted and how it was carried out. FDA inspections are particularly important for companies looking to resolve earlier Official Action Indicated (OAI) citations that prevent the filing of new applications and limit business opportunities. And manufacturers looking to bring new drugs to market usually require a pre-approval inspection (PAI) for final approval. But as the recent surge in COVID-19 cases in the U.S. further delays state and local reopening, FDA is under pressure to devise new strategies for meeting application review deadlines set by user fees that increasingly involve drugs and medical products from facilities that were not inspected prior to the pandemic.
FDA now says it will resume “prioritized” domestic inspections in local areas able to reduce new COVID-19 cases and hospitalizations. Based on a state’s phase of reopening and local trend and intensity of infection, the plan is to determine where the agency can
One surprise is that FDA stated it will pre-announce all prioritized inspections, an approach that is routine overseas, but not at home. The agency explains that providing time to plan for site visits in advance will enhance the safety of both the inspectors and of company staff and also ensure that appropriate personnel are on-site when needed.
Going virtual?
All these challenges raise the prospect that FDA may be conducting fewer on-site inspections in the coming months and will look to tap policies and programs that provide alternative oversight approaches. FDA gained more explicit authority under the FDA Safety and Innovation Act (FDASIA) of 2012 to use new methods to track manufacturing operations in the U.S. and abroad, initially to reduce drug shortages linked to an increasingly global pharmaceutical supply chain. The legislation established a risk-based approach for determining inspection frequency, strengthened FDA’s authority to take action against manufacturers that refuse or delay an inspection, and authorized the agency to request and access manufacturer records
This “in lieu of” provision for obtaining manufacturing records is considered key to providing a framework for more virtual or “records-only” inspections, according to experts participating in a recent webinar hosted by the Food and Drug Law Institute (FDLI). So far, FDA has been reluctant to conduct full remote inspections, but has accessed records for less formal “assessments” to help determine the need for and timing of a site visit. FDA
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
- FDA Expands Transparency With Daily Adverse Event Reporting
August 25th 2025